220 related articles for article (PubMed ID: 37837931)
1. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract][Full Text] [Related]
2. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
[TBL] [Abstract][Full Text] [Related]
4. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
Patrizi S; Miele E; Falcone L; Vallese S; Rossi S; Barresi S; Giovannoni I; Pedace L; Nardini C; Masier I; Abballe L; Cacchione A; Russo I; Di Giannatale A; Di Ruscio V; Salgado CM; Mastronuzzi A; Ciolfi A; Tartaglia M; Milano GM; Locatelli F; Alaggio R
Clin Epigenetics; 2024 Jan; 16(1):9. PubMed ID: 38178234
[TBL] [Abstract][Full Text] [Related]
5. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
6. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.
Mantripragada KK; Spurlock G; Kluwe L; Chuzhanova N; Ferner RE; Frayling IM; Dumanski JP; Guha A; Mautner V; Upadhyaya M
Clin Cancer Res; 2008 Feb; 14(4):1015-24. PubMed ID: 18281533
[TBL] [Abstract][Full Text] [Related]
7. Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53.
Høland M; Kolberg M; Danielsen SA; Bjerkehagen B; Eilertsen IA; Hektoen M; Mandahl N; van den Berg E; Smeland S; Mertens F; Sundby Hall K; Picci P; Sveen A; Lothe RA
Mod Pathol; 2018 Nov; 31(11):1694-1707. PubMed ID: 29946184
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
[TBL] [Abstract][Full Text] [Related]
9. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
10. Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy.
Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Parney IF; Spinner RJ
J Neurooncol; 2023 Sep; 164(3):693-699. PubMed ID: 37755632
[TBL] [Abstract][Full Text] [Related]
11. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis.
Koga T; Iwasaki H; Ishiguro M; Matsuzaki A; Kikuchi M
J Pathol; 2002 May; 197(1):98-107. PubMed ID: 12081210
[TBL] [Abstract][Full Text] [Related]
12. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumours.
Panse G; Leung CH; Ingram DR; Wani K; Torres KE; Lin H; Lazar AJ; Wang WL
Histopathology; 2017 May; 70(6):946-953. PubMed ID: 27992966
[TBL] [Abstract][Full Text] [Related]
13. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
Suppiah S; Mansouri S; Mamatjan Y; Liu JC; Bhunia MM; Patil V; Rath P; Mehani B; Heir P; Bunda S; Velez-Reyes GL; Singh O; Ijad N; Pirouzmand N; Dalcourt T; Meng Y; Karimi S; Wei Q; Nassiri F; Pugh TJ; Bader GD; Aldape KD; Largaespada DA; Zadeh G
Nat Commun; 2023 May; 14(1):2696. PubMed ID: 37164978
[TBL] [Abstract][Full Text] [Related]
14. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
[TBL] [Abstract][Full Text] [Related]
15. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.
Cortes-Ciriano I; Steele CD; Piculell K; Al-Ibraheemi A; Eulo V; Bui MM; Chatzipli A; Dickson BC; Borcherding DC; Feber A; Galor A; Hart J; Jones KB; Jordan JT; Kim RH; Lindsay D; Miller C; Nishida Y; Proszek PZ; Serrano J; Sundby RT; Szymanski JJ; Ullrich NJ; Viskochil D; Wang X; Snuderl M; Park PJ; Flanagan AM; Hirbe AC; Pillay N; Miller DT;
Cancer Discov; 2023 Mar; 13(3):654-671. PubMed ID: 36598417
[TBL] [Abstract][Full Text] [Related]
16.
Wei M; Fan J; Peng R; Ding X; Xi J; Huang H
Front Biosci (Landmark Ed); 2023 Sep; 28(9):214. PubMed ID: 37796695
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group.
Mertens F; Dal Cin P; De Wever I; Fletcher CD; Mandahl N; Mitelman F; Rosai J; Rydholm A; Sciot R; Tallini G; van Den Berghe H; Vanni R; Willén H
J Pathol; 2000 Jan; 190(1):31-8. PubMed ID: 10640989
[TBL] [Abstract][Full Text] [Related]
18. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
[TBL] [Abstract][Full Text] [Related]
19. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
20. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours.
Karube K; Nabeshima K; Ishiguro M; Harada M; Iwasaki H
J Clin Pathol; 2006 Feb; 59(2):160-5. PubMed ID: 16443732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
